zPredicta acquired by Predictive Oncology (NASDAQ:POAI)

Cell culture model for anti-cancer therapeutics
Reading Time: < 1 minute

Predictive Oncology Acquires zPREDICTA

The full press release, originally posted on www.einnews.com, is available here.

External links are provided solely as a convenience to readers and they do not imply an affiliation, sponsorship, endorsement, approval, investigation, verification, or monitoring by Hubble Investments or any of its affiliates of the contents on such third-party websites.

In 2016, Propel(x) offered the opportunity to invest in zPredicta’s seed round.

Accredited investors who are interested in learning more about zPredicta’s seed round, may view their closed profile from 2016 after completing registration.


Start Investing Today​